Pfizer is working on a pill to combat COVID-19.
The company announced that its first participant entered the second trial phase of the three-phase study of its oral antiviral. The pill is intended to mitigate symptoms and hospitalizations.
The treatment is administered in 12-hour increments for five days to people who are symptomatic but not hospitalized. The trial will consist of 1,140 participants who will either receive the pill or a placebo.
If successful, Pfizer’s oral antiviral could help alleviate the strains on health care systems, as the treatment could help reduce the number of hospitalizations.